1-(1,2-二苯基乙基)哌嗪 | 88144-93-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1-(1,2-二苯基乙基)哌嗪
• 英文名称: 1-(1,2-diphenylethyl)piperazine
• 英文别名: 1,2-diphenylethylpiperazine；N-(1,2-Diphenylethyl)-piperazin
• CAS: 88144-93-8
• 化学式: C₁₈H₂₂N₂
• 分子量: 266.386
• InChiKey: NIBIYLDNVMUKNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(5-bromopentyl)-6-chloro-1,2,3,4-tetrahydroacridin-9-amine 、 1-(1,2-二苯基乙基)哌嗪 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以60 mg的产率得到6-chloro-Ν-(5-(4-(1,2-diphenylethyl)piperazin-1-yl)pentyl)-1,2,3,4-tetrahydroacridine-9-amine
  参考文献：
  名称：

  氢化吖啶衍生物及其应用

  摘要：

  本发明涉及化学合成领域，特别涉及通式为Y-L-X的化合物及其作为钙通道阻滞剂或/和乙酰胆碱酯酶抑制剂的应用。通式为Y-L-X的化合物可以调节钙体内稳态、治疗心血管疾病、中风或痴呆。

  公开号：

  CN103524413B
• 作为产物：
  描述：

  1-tert-butyl 4-[1H-1,2,3-benzotriazol-1-yl (phenyl) methyl]piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-(1,2-二苯基乙基)哌嗪
  参考文献：
  名称：

  N-(1,2-Diphenylethyl)piperazines: A new class of dual serotonin/noradrenaline reuptake inhibitor

  摘要：

  The synthesis and structure-activity relationships of a novel series of piperazine derivatives as dual inhibitors of serotonin and noradrenaline reuptake is described. Two compounds possessed comparable in vitro profiles to the dual reuptake inhibitor duloxetine. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.051

文献信息

• 4,4-Biarylpiperidine derivatives
  申请人：——

  公开号：US20020013321A1

  公开（公告）日：2002-01-31

  The present invention relates to compounds of the formula I, 1 wherein Z 1 , Z 2 , R 1 , R 2 and R 3 are defined as in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and gastrointestinal disorders.

  本发明涉及式I化合物，其中Z1、Z2、R1、R2和R3如说明书中所定义，包含此类化合物的药物组合物以及使用此类化合物治疗神经系统和胃肠道疾病的方法。
• 1-Diphenylmethyl-pyrazole derivatives as opioid receptor ligands
  申请人：——

  公开号：US20030069241A1

  公开（公告）日：2003-04-10

  This invention relates to 1-diphenylmethyl-pyrazole derivatives of formula (I): 1 and pharmaceutically acceptable salts thereof; wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined herein, as ligands for opioid receptors, particularly the delta opioid receptor. The compounds of the invention have a broad range of therapeutic uses in the area of addictions, analgesia, immunotherapy, shock and brain injuries, neurological dysfunction, gastrointestinal dysfunction, among others.

  这项发明涉及式(I)的1-二苯甲基吡唑衍生物及其药学上可接受的盐；其中R1、R2、R3、R4和R5在此处定义为阿片受体的配体，特别是δ阿片受体。该发明的化合物在成瘾、镇痛、免疫疗法、休克和脑损伤、神经功能障碍、胃肠功能障碍等领域具有广泛的治疗用途。
• 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives
  申请人：Pfizer Inc

  公开号：US20040063940A1

  公开（公告）日：2004-04-01

  The present invention relates to compounds of the formula I, 1 wherein Z 1 , Z 2 , X, Q, R 1 , R 2 and R 3 are defined as in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and gastrointestinal disorders.

  本发明涉及公式I的化合物，其中Z1，Z2，X，Q，R1，R2和R3如规范中所定义，含有这种化合物的制药组合物以及使用这种化合物治疗神经和胃肠障碍的方法。
• Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
  申请人：Bish Gerwyn

  公开号：US20070105870A1

  公开（公告）日：2007-05-10

  A compound of formula (I), wherein R 1 is H; R 2 is aryl, het, C 3-8 cycloalkyl, C 1-6 alkyl, (CH 2 ) 2 aryl or R 4 , wherein each of the cycloalkyl, aryl, het and R 4 groups is optionally substituted by at least one substituent independently selected from C 1-6 alkyl, C 1-6 alkoxy, OH, halo, CF 3 , OCF 3 , OCHF 2 , O(CH 2 ) y CF 3 , CN, CONH 2 , CON(H)C 1-6 alkyl, CON(C 1-6 alkyl) 2 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-4 alkoxy, SCF 3 , C 1-6 alkyISO 2 , C 1-4 alkyl-S-C 1-4 alkyl, C 1-4 alkyl-S—, C 1-4 alkyINR 10 R 11 and NR 10 R 11 ; or R 1 and R 2 , together with the carbon atom to which they are bound, form a 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle containing at least one N, O or S heteroatom; R 3 is aryl, het or R 4 , each optionally substituted by at least one substituent independently selected from C 1-6 -alkyl, C 1-6 -alkoxy, het, OH, halo, CF 3 , OCF 3 , OCHF 2 , O(CH 2 ) y CF 3 , CN, CONH 2 , CON(H)C 1-6 alkyl, CON(C 1-6 alkyl) 2 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-4 alkoxy, SCF 3 , C 1-6 alkyISO 2 , C 1-4 alkyl-S-C 1-4 alkyl, C 1-4 alkyl-S—, C 1-4 alkylNR 10 R 11 and NR 10 R 11 ; R 4 is a phenyl group fused to a 5- or 6 membered carbocycle, or a phenyl group fused to a 5- or 6-membered heterocycle containing at least one N, O or S heteroatom; R 5 is H or C 1-6 alkyl; R 10 and R 11 are the same or different and are independently H or C 1-4 alkyl; A is a C 1-3 alkylene chain which is optionally substituted by OH, C 1-4 alkyl or C 1-4 alkoxy; x is an integer from 1 to 3; y is 1 or 2; z is an integer from 1 to 3; aryl is phenyl, naphthyl, anthracyl or phenanthryl; and het is an aromatic or non-aromatic 4, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocycle or a second 4, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom.

  化合物的化学式为（I），其中R1为H; R2为芳基，杂环，C3-8环烷基，C1-6烷基，（CH2）2芳基或R4，其中环烷基，芳基，杂环和R4基团中的每一个都可以独立地被至少一个取代基取代，所述取代基从C1-6烷基，C1-6烷氧基，OH，卤素，CF3，OCF3，OCHF2，O（CH2）yCF3，CN，CONH2，CON（H）C1-6烷基，CON（C1-6烷基）2，羟基-C1-6烷基，C1-4烷氧基-C1-6烷基，C1-4烷氧基-C1-4烷氧基，SCF3，C1-6烷基ISO2，C1-4烷基-S-C1-4烷基，C1-4烷基-S-，C1-4烷基INR10R11和NR10R11中独立选择; 或者R1和R2与它们所连接的碳原子一起形成一个含有至少一个N，O或S杂原子的5-或6-成员碳环或5-或6-成员杂环; R3为芳基，杂环或R4，每个都可以独立地被至少一个取代基取代，所述取代基从C1-6烷基，C1-6烷氧基，杂环，OH，卤素，CF3，OCF3，OCHF2，O（CH2）yCF3，CN，CONH2，CON（H）C1-6烷基，CON（C1-6烷基）2，羟基-C1-6烷基，C1-4烷氧基-C1-6烷基，C1-4烷氧基-C1-4烷氧基，SCF3，C1-6烷基ISO2，C1-4烷基-S-C1-4烷基，C1-4烷基-S-，C1-4烷基NR10R11和NR10R11中独立选择; R4是融合到5-或6-成员碳环中的苯基或融合到至少一个N，O或S杂原子的5-或6-成员杂环中的苯基; R5为H或C1-6烷基; R10和R11相同或不同，独立地为H或C1-4烷基; A为C1-3烷基链，可以选择地被OH，C1-4烷基或C1-4烷氧基取代; x为1到3的整数; y为1或2; z为1到3的整数; 芳基为苯基，萘基，蒽基或菲基; 杂环为含有至少一个N，O或S杂原子的芳香或非芳香4、5-或6-成员杂环，可以选择地融合到一个5-或6-成员碳环或第二个含有至少一个N，O或S杂原子的4、5-或6-成员杂环中。
• 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
  申请人：Pfizer Products Inc.

  公开号：EP1038872A1

  公开（公告）日：2000-09-27

  The present invention relates to compounds of the formula I, wherein Z1, X, Y, ( )n, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds; and the use of such compounds to treat neurological and gastrointestinal disorders.

  本发明涉及式 I 的化合物、 其中 Z1、X、Y、( )n、R1、R2 和 R3 的定义如说明书中所述；含有此类化合物的药物组合物；以及使用此类化合物治疗神经和胃肠疾病。